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Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor
neurons in the CNS and leading to paralysis and death. There are currently no effective treatments for ALS due to
the complexity and heterogeneity of factors involved in motor neuron degeneration. A complex of interrelated
effectors have been identified in ALS, yet systemic factors indicating and/or reflecting pathological disease
developments are uncertain. The purpose of the study was to identify humoral effectors as potential biomarkers
during disease progression.
Methods: Thirteen clinically definite ALS patients and seven non-neurological controls enrolled in the study. Peripheral
blood samples were obtained from each ALS patient and control at two visits separated by 6 months. The Revised ALS
Functional Rating Scale (ALSFRS-R) was used to evaluate overall ALS-patient functional status at each visit. Eleven
humoral factors were analyzed in sera. Cytokine levels (GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α)
were determined using the Bio-Rad Bio-Plex® Luminex 200 multiplex assay system. Nitrite, a breakdown product of NO,
was quantified using a Griess Reagent System. Glutathione (GSH) concentrations were measured using a Glutathione
Fluorometric Assay Kit.
Results: ALS patients had ALSFRS-R scores of 30.5 ± 1.9 on their first visit and 27.3 ± 2.7 on the second visit, indicating
slight disease progression. Serum multiplex cytokine panels revealed statistically significant changes in IL-2, IL-5, IL-6, and
IL-8 levels in ALS patients depending on disease status at each visit. Nitrite serum levels trended upwards in ALS patients
while serum GSH concentrations were drastically decreased in sera from ALS patients versus controls at both visits.
Conclusions: Our results demonstrated a systemic pro-inflammatory state and impaired antioxidant system in ALS
patients during disease progression. Increased levels of pro-inflammatory IL-6, IL-8, and nitrite and significantly
decreased endogenous antioxidant GSH levels could identify these humoral constituents as systemic biomarkers
for ALS. However, systemic changes in IL-2, IL-5, and IL-6 levels determined between visits in ALS patients might
indicate adaptive immune system responses dependent on current disease stage. These novel findings, showing
dynamic changes in humoral effectors during disease progression, could be important for development of an
effective treatment for ALS.
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Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease that affects motor neurons in the brain and
spinal cord leading to paralysis and eventually death,
usually within 3 to 5 years of diagnosis. There are two
recognized variants of ALS, sporadic ALS (SALS) and
familial ALS (FALS). The vast majority (90–95 %) of all
ALS cases is sporadic (SALS) while the remaining FALS
cases are genetically linked [1, 2]. Within FALS cases,
approximately 20 % result from missense mutations in
the gene coding for Cu/Zn superoxide dismutase (SOD1)
[3, 4] and about 2–5 % have mutations of the TARDBP
gene encoding the TAR-DNA-binding protein TDP-43
[5]. Interestingly, mutations in the TARDBP gene have
been found in both FALS and SALS [6, 7]. The clinical
presentation and underlying pathology of SALS and FALS
are similar, and treatment options for ALS patients are
limited and mainly supportive. Current drug therapy, such
as riluzole (Rilutek®), extends the lifespan of ALS patients
by only a few months [8, 9].
Although numerous hypotheses about the etiopathol-
ogy of ALS have been proposed (reviewed in [10–14]),
the complexity and heterogeneity of factors involved in
motor neuron degeneration represent a major challenge
to developing effective therapies for ALS. A combination
of interrelated effectors such as glutamate excitotoxicity,
mitochondria dysfunction, glial cell pathology, impaired
axonal transport, protein aggregations, and neurotrophic
factor deficits leads to progressive motor neuron degen-
eration and eventual death.
Additionally, oxidative stress [15–18] and neuroin-
flammation [19–24] have been implicated in both SALS
and FALS motor neuron degeneration and are consid-
ered important components in ALS pathogenesis. These
effectors have been identified in spinal cords, cerebro-
spinal fluid (CSF), and blood collected from ALS pa-
tients. In CSF, dysregulation in expression of anti- and
pro-inflammatory cytokines and growth factors, such as
interferon-gamma (IFN-γ), tumor necrosis factor-alpha
(TNF-α), interleukins (IL)-6 and IL-10, and vascular
endothelial factor (VEGF), have been noted [25]. Systemic
inflammatory cytokines such as TNF-α, interferon-beta
(IFN-β), and various interleukins exacerbating cognitive
and motor dysfunction have been identified in various
neurodegenerative diseases, including ALS [26–29]. More-
over, several studies demonstrated specific biomarkers in
CSF and plasma which might distinguish patients with
ALS from other neurological diseases [4, 25] and even
predict ALS prognosis [30]. Su et al. [30] showed that par-
ticular cytokines found in plasma of ALS patients predict
shorter (IL-1β and IL-12) or longer (IL-10) disease dur-
ation and suggested that a lesser degree of inflammation
might be associated with longer disease duration. How-
ever, it has been noted that biomarkers in plasma, mainlyindicating ongoing inflammatory processes in ALS pa-
tients, might differ from CSF biomarkers [31].
Nitric oxide (NO), a gasotransmitter, has also been
shown as a significant contributor in ALS pathogenesis
by glutamate-induced neuronal death (reviewed in [32]).
NO-related toxicity promotes inflammation through the
formation of peroxynitrite that results in disruption of
the mitochondrial respiratory chain, production of react-
ive oxygen species (ROS), and glutamate toxicity [32].
Elevated NO has also been found in patients with other
pro-inflammatory conditions such as arthritis [33] and
acute pancreatitis [34]. Reductions in glutathione, a
component of the endogenous antioxidant system, have
been shown in numerous neurodegenerative diseases
such as Parkinson’s disease, Alzheimer’s disease, schizo-
phrenia, and ALS, leading to increased concentrations of
ROS (reviewed in [35]). Also, significantly decreased
glutathione levels were noted in the blood of patients
with Friedreich’s ataxia, suggesting that impairment of
glutathione homeostasis involved in free radical cytotox-
icity contributes to disease pathogenesis [36]. In ALS,
however, the role of glutathione is still unclear. The ac-
tivity of the enzyme glutathione peroxidase was normal
[37] or reduced [38] in the spinal cord or brain of ALS
patients and also reduced in the blood of SALS patients
[39]. It is important to establish specific systemic bio-
markers which can easily be monitored in the clinic,
serve as a novel diagnostic tool, or verify treatment effi-
cacy for ALS [40]. Particularly, the identification of
humoral markers related to oxidative and/or inflamma-
tory status in ALS may have essential implications. To
date, only a few human ALS studies (referenced above)
have identified specific systemic effectors; however, levels
of these effectors have yet to be correlated with disease
progression in ALS patients.
In this study, we endeavor to characterize humoral ef-
fectors in ALS patients during disease progression. It is
essential to establish which inflammatory and oxidative
effectors are present, altered, and/or might reflect dis-
ease status. Most importantly, identifying major humoral
effectors as biomarkers in ALS is key to improved un-




Thirteen clinically definite ALS patients (12 males and 1 fe-
male, mean age 53.9 ± 2.8 years) and seven healthy controls
(3 males and 4 females, mean age 57.7 ± 5.7 years) entered
our study. Demographic information of all study subjects is
provided in Table 1. ALS patients and control subjects vis-
ited the University of South Florida (IRB #103861) clinic
twice; each visit was separated by 6 months. The diagnoses
of ALS were previously established according to the EI
Table 1 Demographic information of ALS patients and healthy
controls
ALS patients Healthy controls
n 13 7
Age (years) mean ± SEM 53.85 ± 2.81 57.71 ± 5.73
Range, 38–68 Range, 37–69
Sex (male/female) 12/1 3/4
ALSFRS-R mean ± SEM first visit 30.46 ± 1.93 48.0 ± 0.0
Range, 21–41
ALSFRS-R mean ± SEM second visit 27.25 ± 2.73 N/A
Range, 21–38
Disease duration from onset
(months) at first visit mean ± SEM
41.77 ± 7.53 N/A
Range, 11–96
Disease duration from diagnosis
(months) at first visit mean ± SEM
21.00 ± 4.44 N/A
Range, 5–53
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various ALS clinics/centers. The Revised ALS Functional
Rating Scale (ALSFRS-R), scored from 0 to 48, was used
to evaluate overall patient functional status [43]. The
ALSFRS-R score was updated for each patient when
blood was drawn. Control subjects had no neurological,
immunological, or psychiatric comorbidities.
Ethics, consent, and permission
This study was approved by the Institutional Review
Board at the University of South Florida (IRB #103861).
Each participant in the study signed an informed consent
form prior to enrollment.
Collection and processing of blood specimens
Two sets of peripheral blood samples (~90 ml each set)
were obtained by venipuncture from each patient and
healthy control at -month intervals in accordance with
previously described study protocols [44]. Briefly, blood
was drawn and collected into a sterile 10-ml tube with a
silicone-coated interior (BD Vacutainer, Serum, REF
367820) containing a clot activator. The 10-mL serum
tube was placed in a 37 °C incubator for 60 min, allow-
ing the blood to clot, and then stored overnight at 4 °C.
The next day, the supernatant was decanted into a 15-mL
sterile conical centrifuge tube and centrifuged at 400×g
for 10 min at 4 °C. After centrifugation, sera transferred to
sterile 1.5-mL tubes and stored at −20 °C until assayed.
Additionally, a portion of each collected blood sample was
sent to the Oklahoma Blood Institute (Oklahoma, OK) for
infectious disease (HIV, hepatitis B and C, syphilis, CMV,
and HTLV I&II) testing.
Humoral cytokine detection
A human ultrasensitive cytokine 10-plex panel (Invitrogen;
LHC6004) was employed to determine various cytokineconcentrations within the sera samples from ALS patients
and controls. All cytokine measurements were performed
blind by independent investigators to avoid subjective bias.
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) and cytokine levels (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
8, IL-10, and TNF-α) were determined using the Bio-Rad
Bio-Plex® Luminex 200 multiplex assay system. Briefly, a
dilution of capture antibody-labeled beads was added to a
96-well filter bottom plate and washed twice with the
supplied wash buffer. Washing steps were performed
according to the manufacturer’s protocol using vacuum
manifold. Samples (1:2 dilution) or standards (supplied
in the kit) were then added to their respective wells in
duplicate. The plate was then sealed with an adhesive
strip and incubated on a plate shaker for 2 h at room
temperature (RT). After incubation, the plate was washed
twice with the supplied wash buffer and the diluted biotin
conjugated detection antibody added. The plate was sealed
and allowed to incubate again for 1 h, shaking at RT. Then
the wells were washed twice with wash buffer, and diluted
streptavidin-RPE reporter reagent (diluted following man-
ufacturer’s instructions) was added to all wells. The plate
was incubated again for 30 min while shaking at RT. Fi-
nally, the plate was washed three more times with buffer
to remove unbound streptavidin-RPE. The analtye/bead
complex was then resuspended in 100 μL of wash buffer
by shaking for 5 min before analysis. Standard and sample
cytokine concentrations were then calculated using the
Bio-Rad Bio-Plex® 200 software and results displayed as pg
of analyte per mL of sera.
Serum nitrite detection
Nitrite (NO2
−), a stable and nonvolatile breakdown prod-
uct of NO, was measured in sera samples using a Griess
Reagent System (Promega, Madison, WI) as described
previously [33, 45] and per the manufacturer’s instruc-
tions. The nitrite measurements were performed blind
by independent investigators to avoid subjective bias.
Briefly, nitrite standards were prepared in triplicate in
fetal bovine serum diluent. The 50 μL of each serum
sample were dispensed into a 96-well plate. Sulfanila-
mide solution (50 μL) was added to each well using a
multichannel pipettor, and the plate was incubated for
10 min at RT. Next, 50 μL of N-1-naphthyl ethylenedi-
amine dihydrochloride solution was added to each well.
Following a 10-min incubation at RT, absorbance was
measured using a plate reader (Spectramax Plus 384) set
to a wavelength of 530 nm. Nitrite concentrations (μM)
were determined by comparing absorbance values to the
standard curve.
Serum glutathione detection
Glutathione (GSH) concentrations were measured using
a Glutathione Fluorometric Assay Kit (BioVision, cat.
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structions. The GSH measurements were performed
blind by independent investigators to avoid subjective
bias. Briefly, 60 μL of serum was added in 20 μL of 6 N
Perchloric acid (PCA). Samples were put on ice for 5
min and centrifuged for 2 min at 13,000×g at 4 °C, and
40 μL of supernatant was collected for assay. To precipi-
tate PCA, 20 μL of 6 N potassium hydroxide was added
to samples and incubated on ice for 5 min. Samples were
then centrifuged for 2 min at 13,000×g at 4 °C, and 10 μL
of supernatant were transferred to a 96-well plate. To de-
tect GSH, samples were brought up to 90 μL with assay
buffer and incubated with 10 μL of o-phthalaldehyde probe
for 40 min at RT. Fluorescence readings were measured
using a fluorescence plate reader (Spectramax Gemini EM)
at 340/420 nm (Ex/Em wavelength). Results are displayed
as μg/mL.
Statistical analysis
Data are presented as means ± S.E.M. Statistical analysis
was performed using GraphPad Prism software (Graph-
Pad Software, Inc.). Two-tailed t-tests were used, with
p < 0.05 considered significant.
Results
Subject demographics
Blood from 13 ALS patients and 7 healthy controls was
collected at two visits, 6 months apart. Patients had been
diagnosed with ALS for 21.0 ± 4.44 months (range, 5–53
months) with ALSFRS-R scores of 30.46 ± 1.93 on the first
visit. Twelve ALS patients were Caucasian and one was
African American. The mean time since the onset of ALS
symptoms in this patient population was 41.77 ± 7.53
(range, 11–96) months. After 6 months, ALSFRS-R scores
of ALS patients decreased to 27.25 ± 2.73 (Table 1) indi-
cating slight progression of disease. Although there was
no significant difference in ALSFRS-R scores of ALS pa-
tients (p < 0.08) between visits, a substantial decrease in
ALSFRS-R scores (6–9 points) was determined in six pa-
tients. Scores were unchanged in three ALS patients. Each
healthy control scored 48. ALS patients were taking a
standard dose of riluzole. One patient refused to take rilu-
zole. Eleven ALS patients had sporadic disease onset at
upper, lower, or both limbs. Two patients had familial
ALS. No patients had bulbar onset. All study participants
tested negative for infectious diseases (HIV, hepatitis B
and C, syphilis, CMV, and HTLV I and II).
Humoral cytokine profile
Serum samples from ALS patients and controls were
assayed using an ultrasensitive human cytokine 10-plex
panel. At the first visit, significant (p < 0.05) down-
regulation of IL-5 and up-regulation of IL-6 levels were
detected in sera of ALS patients compared to controls(Fig. 1). Elevated serum IL-1β and IL-8 levels were deter-
mined in ALS patients, although not differing significantly
(p > 0.05) from control subjects. Also, non-significant
decreases (p > 0.05) of IL-2 and GM-CSF levels were
observed in ALS patients versus controls.
At the second visit (6 months later), serum cytokine pro-
file in ALS patients changed (Fig. 1). Significant (p < 0.05)
decreases of IL-2 levels showed in sera of ALS patients
compared to controls. In contrast to the first visit, IL-5
levels in sera of ALS patients were similar to levels of
control subjects. Serum IL-6 levels in ALS patients were
also similar to control levels, being significantly (p < 0.01)
reduced versus initial ALS-patient visits. Significant
(p < 0.01) increases of IL-8 cytokine levels were found in
sera of ALS patients. Similarly to the first visit, non-
significantly elevated IL-1β levels were observed in sera of
ALS patients after 6 months (p > 0.05). Serum TNF-α
levels were also similar in ALS patients at both visits
compared to controls. Although IL-4 levels were slightly
reduced in sera of ALS patients at both visits, these de-
creases were not statistically significant (p > 0.05). Also,
there were no significant differences in serum IL-10 levels
at either visit between patients and controls (Fig. 1).
Humoral nitrite levels
Serum samples were assayed to measure concentrations of
nitrite, a breakdown product of NO. At both visits, sera
from ALS patients contained higher concentrations of ni-
trite (first visit—65.33 ± 12.38 μM, second visit—69.12 ±
21.29 μM) than the control sera (first visit—44.94 ± 9.32
μM, second visit—36.01 ± 3.70 μM) (Fig. 2). However, con-
centration was higher in ALS sera with a slight increase at
the second visit of ALS patients; differences versus controls
were not statistically significant (p = 0.09) at either visit.
Humoral glutathione levels
Serum samples were assayed to measure glutathione (GSH)
concentrations using a Glutathione Fluorometric Assay.
Results showed that sera from ALS patients had drastically
lower GSH levels (first visit—22.25 ± 0.99 μg/mL, second
visit—30.33 ± 2.68 μg/mL) compared to controls (first
visit—131.54 ± 12.05 μg/mL, second visit—140.25 ± 9.31
μg/mL) at both visits (p < 0.001) (Fig. 3).
Discussion
In the present study, humoral factors, as potential bio-
markers of ALS, were examined in ALS patients during
disease progression. Various pro- and anti-inflammatory
cytokines including GM-CSF, nitrite, and glutathione
concentrations in sera of ALS patients and age-matched
control subjects were evaluated after each of two visits,
6 months apart. The major findings in our study were as
follows: 1) significant increase of IL-6 in ALS patients at
the first visit was not noted at the second visit; 2)
Fig. 1 Serum multiplex cytokine panel. Cytokine profile was assayed in sera of ALS patients and controls on both visits using an ultrasensitive human
cytokine panel. At first visit, a significant increase in serum IL-6 (p < 0.05) and decrease in IL-5 (p < 0.05) levels were determined for ALS patients versus
controls. At second visit, ALS patients had significantly less serum IL-2 (p < 0.05) and IL-6 (p < 0.01) although IL-8 increased (p < 0.01) compared
to controls. There were no significant differences in IL-1β, TNF-α, IL-4, IL-10, and GM-CSF between ALS patients and controls, although elevated
IL-1β and decreased IL-4 and GM-CSF were noted in both visits. Results are plotted as mean ± SEM. Statistical significance was determined
using two-tailed t-tests (* p < 0.05, ** p < 0.01)
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the second visit of ALS patients; 3) initial decrease of
IL-2 was significantly lower in ALS patients at the sec-
ond visit compared to healthy controls; 4) significant de-
crease of IL-5 levels in ALS patients at the first visit was
not present at the second visit; 5) elevated nitrite con-
centrations were determined in both visits of ALS pa-
tients; 6) significantly lower glutathione concentrations
were found in ALS patients at both visits. These results
suggest that specific humoral factors might represent
inflammatory and oxidative stress responses in ALS with
dynamic changes during disease progression.
Comprehensive studies have demonstrated a central
role for inflammation in motor neuron degeneration and
death in ALS. Large numbers of activated microglia and
reactive astrocytes along with infiltration of inflamma-
tory cells have been observed in the brainstem andspinal cord in both ALS patient and animal models
[20, 24, 46–53]. These inflammatory effectors are capable
of secreting numerous cytokines playing key roles in the
inflammatory reaction leading to motor neuron damage.
Although sufficient evidence exists of inflammatory reac-
tions in ALS, the role of inflammation in the selective
motor neuron death occurring during disease progression
in ALS is still unclear and might depend upon disease
stage. However, studies have demonstrated a neuroprotec-
tive role of inflammation in slowing disease progression
by involvement of T-regulatory (Treg)/Th2 immune
system activity [54–57]. This activity contributed to anti-
inflammatory neuroprotective immune responses that reg-
ulated and/or opposed deleterious pro-inflammatory-
mediated ALS progression. In both animal models and
ALS patients, the endogenous T lymphocytes, specifically
Treg cells, increased at an early slowly progressing disease
Fig. 2 Serum nitrite levels. Nitrite concentrations were assayed in sera of
ALS patients and controls at both visits using a Griess Reagent System.
Nitrite levels were higher in ALS sera than control sera on both visits,
but the differences were not statistically significant (p = 0.09). Results are
plotted as mean ± SEM. Statistical significance was determined using
two-tailed t-tests (* p < 0.05, ** p < 0.01)
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rapid ALS progression, likely due to the loss of FoxP3,
a transcription factor for Treg function [54, 58]. Thus,
endogenous Treg lymphocytes actively contribute to
neuroprotection in ALS likely via interactions with
protective M2 microglia and increased levels of these T
cells in ALS patients might have therapeutic value and
“slow the rate of disease progression and stabilize patients
for longer periods of time” [58]. Though, establishing spe-
cific interactions between central and peripheral inflam-
matory processes in ALS might be critical not only for
understanding additional disease mechanisms, but mayFig. 3 Serum glutathione levels. Glutathione (GSH) concentrations
were assayed in sera of ALS patients and controls at both visits
using a Glutathione Fluorometric Assay Kit. Dramatically lower GSH
levels (*** p < 0.001) were determined in sera of ALS patients at both
visits compared to controls. Results are plotted as mean ± SEM. Statistical
significance was determined using two-tailed t-tests (*** p < 0.001)also have “important implications for therapy” (reviewed
in [24]). To support this notion, Zhang et al. [59] found
increased expression of HLA-DR (a MHC class II cell sur-
face receptor) on monocytes and macrophages in the
blood of SALS patients relating to the rate of disease pro-
gression, suggesting a link between systemic macrophage
activation and ongoing CNS pathogenic processes.
The elevated cytokines found in sera from ALS pa-
tients are predominantly secreted by activated mono-
cytes/macrophages and might be important mediators of
the peripheral inflammatory response either promoting a
neuroprotection or accelerating disease progression. Ele-
vated IL-6 cytokine levels have been noted in sera from
ALS patients [60]. Also, levels of this cytokine were sig-
nificantly higher in CSF from ALS patients than from
patients with other neurological diseases [61]. Our study
confirms previous results [60], noting significant increases
of IL-6 levels in ALS-patient sera only at the first visit.
However, IL-6 was reduced to control levels by the second
visit. This interleukin is a bi-functional cytokine, which
can act as a pro-inflammatory cytokine and an anti-
inflammatory myokine. IL-6 is secreted by T lymphocytes
and macrophages during infection, stimulating immune
response [62–64] and serving as a pro-inflammatory me-
diator. The anti-inflammatory role of IL-6 has been mainly
associated with muscle contractions [65, 66] but likely this
is not the case in ALS. Possibly, this cytokine initially acts
as a pro-inflammatory protein in ALS-patient sera and,
upon disease progression, becomes an unreliable marker
of peripheral inflammation. However, since IL-6 can cross
the blood-brain barrier [67], the significant IL-6 sera levels
determined at the first visit of ALS patients might have
been abrogated at the second visit due to infiltration of
this protein per se in addition to extravasation of in-
flammatory cells into the CNS parenchyma. Also, it has
been shown that IL-6 increases might be related to the
hypoxia experienced by some ALS patients and may not
indicate inflammatory status as previously suspected
[68]. Measurements of blood oxygen levels in ALS pa-
tients might be informative in this respect and merit
further investigation.
In accord with significantly elevated IL-6 levels in sera
from ALS patients at the initial visit, IL-8 levels also in-
creased and substantially escalated at the second visit.
The IL-8 is a member of the CXC chemokine family and
is produced by macrophages and other cell types, includ-
ing endothelial cells [69]. This chemokine is primarily
associated with inflammation and is known as a pro-
inflammatory mediator [70] and/or mediator of immune
reaction in the innate immune system response [71]. Al-
though IL-8 predominantly has chemoattractive activity
for neutrophils, this chemokine is also a potent angio-
genic factor [72]. In a study by Kuhle et al. [73], IL-8
and monocyte chemoattractant protein-1 (MCP-1) levels
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patients versus control (non-inflammatory neurological
disease) patients. However, serum levels of these chemo-
kines did not significantly differ between ALS patients and
controls. The authors concluded that increased IL-8 levels
in CSF suggested “stimulation of pro-inflammatory cyto-
kine cascade after microglia activation” and that high
CSF-MCP-1 levels might be associated with rapid disease
progression and short survival time. Nevertheless, use of
these chemokines as prognostic factors for ALS was not
investigated in this study, as the chemokines were ana-
lyzed in CSF and sera from ALS patients only once at
early stage of disease (281 days from first symptoms to
diagnosis). In our study, increased IL-8 levels in sera cor-
related with disease stage, suggesting that this durable
pro-inflammatory mediator might be a useful marker of
inflammation in ALS progression.
Another finding of our study was that IL-2 and IL-5
levels were lower in ALS-patient blood during both visits
with significant decreases in the first (IL-5) and second
(IL-2) visits. IL-2 is an immunoregulatory lymphokine,
which is produced by T cells [74]. This cytokine regu-
lates lymphocyte activity in the immune system, mainly
in response to infection, and promotes the differenti-
ation of immature T cells into both pro-inflammatory T
cell subsets in the Th1/Th17 pathways, resulting in ac-
celeration of disease progression, and anti-inflammatory
regulatory T cells which maintain cellular immunologic
memory to protect the host from reinfection by the
same pathogen [75]. IL-5 is mainly produced by T helper
(Th2) and mast cells and stimulates B cell growth and
activation, increasing antibody production [76]. It is also
involved in eosinophil activation [77, 78] in association
with several allergic diseases [79–81]. In ALS patients,
no significant differences in serum IL-2 levels versus
control subjects were reported [82, 83] suggesting that
this cytokine might have a limited input in the immune
system response, at least in the early stage of disease
(14.3 ± 9.34 months disease duration in [83]). In con-
trast, the significantly decreased IL-2 in sera of ALS pa-
tients at a more pronounced disease stage (42 months
disease duration) demonstrated in our study strengthens
potential down-regulation of this cytokine on differenti-
ation and/or maintenance of all T cell subsets, including
regulatory T cell populations, such as T helper cells, that
might lead to a Th1/Th2 imbalance toward the develop-
ment of an autoimmune disorder [84]. A reduction in
IL-2 cytokine expression can affect not only the prolifer-
ation of pro-inflammatory Th1/Th17 cell subsets pro-
moting ALS progression, but can also increase Treg/Th2
subsets that provide anti-inflammatory stimuli resulting
in protection during an inflammatory event. Also, since
a significant reduction of regulatory T cells (CD4 +
CD25+) and monocytes (CD14+) in blood of sporadicALS patients with less severe disease was noted [85],
suggesting early recruitment of these cells to the CNS
areas of neurodegeneration, it is possible that decreased
serum IL-2 levels in our ALS patients during disease
progression reflects limited guidance of antigen-driven T
cell development. The role of IL-5 in systemic circula-
tion of ALS patients, however, is unclear. Various cyto-
kines are known to modulate the balance between
humoral and cellular immune responses depending on
eminence of antigen activation of B and T lymphocytes
into antibody-producing plasma and T effector cells. For
instance, abnormally high immunoglobulin G (IgG) con-
centrations and IgM/IgA levels within normal ranges
were indicated in sera from ALS patients with early or
moderate disease stages [44, 86, 87]. However, some
studies demonstrated that serum IgG, IgM, or IgA in
ALS patients did not differ from control levels [59, 88]
or found even lower IgG concentrations in patients with
severe disease stage [59]. These conflicting reports on
serum antibody concentrations in ALS might identify
immunological profiles varying with predominant humoral
or cellular immune response. However, our previous data
[44] showing highly elevated serum circulating immune
complexes and IgG levels in sporadic ALS patients during
disease progression suggest that a humoral immune re-
sponse might initiate adaptive immunity in ALS. It is pos-
sible that the significant decrease of serum IL-5 in ALS
patients at the first visit shown in our current study in-
dicated suppression of B cell activation and/or antibody
production, likely due to the existing large amount of
IgG in sera.
Furthermore, our study results showed that levels of
pro-inflammatory cytokines IL-1β and TNF-α in sera
from ALS patients did not significantly differ from con-
trols, although they were elevated during disease pro-
gression. Also, no significant differences were noted in
anti-inflammatory IL-4 and IL-10 cytokine concentra-
tions between ALS patients and control subjects. These
results conflict with previous reports demonstrating in-
creased TNF-α and IL-1β levels in the blood of ALS pa-
tients [89–91]. However, our findings showing mostly
analogous serum IL-1β and TNF-α levels between ALS
patients and controls supported the recent study of
Furukawa T et al. [83], demonstrating similar outcomes.
Furthermore, the infiltration of IL-1β- and TNF-α-
positive macrophages detected in the spinal cord of
sporadic ALS patients but not in controls [28] might
possibly explain the low levels of these cytokines ob-
served in the sera of our ALS patients.
In addition to cytokine/chemokine profiling in sys-
temic circulation of ALS patients during disease progres-
sion, nitrite and glutathione (GSH) were evaluated as
potential biomarkers for this disease. Elevated nitrite
and significantly reduced GSH levels determined in sera
Ehrhart et al. Journal of Neuroinflammation  (2015) 12:127 Page 8 of 11of ALS patients versus controls on both visits in our
study might indicate ongoing oxidative stress, likely due
to prolonged pro- and anti-oxidative imbalances [92]. In-
creased NO and reduced oxidized glutathione levels de-
tected in CSF from sporadic ALS patients suggest that
NO production is activated in ALS and leads to reductions
in superoxide radicals that normally oxidize glutathione
[93]. Also, impairment in activity of glutathione peroxid-
ase, the predominant antioxidant enzyme, was noted in
plasma from sporadic ALS patients, and levels remained
low during disease course [94]. Although numerous stud-
ies showed that oxidative stress plays a substantial role in
motor neuron degeneration in ALS [15–18, 95], some evi-
dence points to oxidative stress as “not just an event in
the CNS but rather a systemic process” leading to the sug-
gestion that “ALS is possibly a systemic disease” [96]. Bio-
markers of oxidative or nitrosative stress were determined
not only in the CNS tissue but also in plasma, urine, and
CSF of ALS patients [97–99]. Moreover, increased oxida-
tive stress and immune activation correlating with disease
progression were demonstrated in serum and CSF of
sporadic ALS patients [98]. Of note, both GSH and NO
levels can fluctuate due to a variety of dietary and envir-
onmental factors [100, 101] and are thus likely non-
specific disease indicators. Glutathione production itself
is directly dependent on the presence of the α-amino
acid cysteine. Essentially, if adequate concentrations of
cysteine are not produced in the body or acquired through
diet, then the major constituent of the endogenous anti-
oxidant system cannot be synthesized, leaving unprocessed
reactive oxygen species in the body and resulting in oxida-
tive damage to cells and tissues. The GSH and NO levels
observed in the systemic compartment in ALS patients
during disease progression lends further credence to the
idea that oxidative stress is an important hallmark of the
pathological changes in ALS.
Numerous studies showed that immune reactivity,
inflammatory processes, and oxidative stress are
actively involved in ALS pathogenesis (reviewed in
[22, 23, 96, 102, 103]). However, it is uncertain which fac-
tor(s) trigger immune, inflammatory systemic response,
and/or pro-oxidative state in this disease. Also, the role of
the immune system as a primary mechanism of motor
neuron degeneration in ALS and/or a secondary response
to inflammation is still unclear. It is known that an innate
immune response is initiated by microglia activation in
ALS and an adaptive immune response might be associ-
ated with inflammation in the CNS. Thus, the systemic
compartment could largely reflect the complexity of the
ALS immune/inflammatory response, including oxidative
stress, depending on disease stage. In support of this
notion, Mantovani et al. [85] provided evidence of
immunological alterations in the blood of ALS patients
associated with ongoing neuroinflammatory processes.Neuroinflammation in ALS is believed to be a prominent
pathological event in areas of motor neuron degeneration.
Both innate and adaptive immune responses might highly
influence disease progression by shifting from beneficial
(neuroprotective) to deleterious (neurotoxic) immune re-
sponses. However, McCombe and Henderson [23] noted
that “It is possible that individual variability in immune re-
sponsiveness means that individual patients have different
immune responses in ALS.” A clear understanding of “the
dynamic changes that occur within the immune system
over the course of disease” [104] is essential for developing
an effective treatment for ALS.
In conclusion, results of the present study indicate a
clear shift toward a systemic pro-inflammatory state and
impaired antioxidant system in ALS patients during dis-
ease progression. This is evidenced by increased pro-
inflammatory humoral factors such as IL-6, IL-8, and
NO and decreased antioxidant glutathione levels. These
constituents could serve as systemic biomarkers of ALS.
However, systemic changes in some interleukin (IL-2,
IL-5, and IL-6) levels determined in the same cohort of
ALS patients might indicate specific adaptive immune
system responses depending on the current disease
stage. Although the concurrence of inflammation, oxida-
tive stress, and immune system alterations in the sys-
temic compartment of ALS patients needs elucidation,
the present study supports the notion that monitoring
dynamic changes of humoral effectors during disease
progression may further our understanding of patho-
logical alterations in ALS. Also, our novel findings
should be considered for endeavors to develop an effect-
ive treatment for ALS.
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